Lazard Capital Markets downgrades Synta Pharmaceuticals (Nasdaq: SNTA) from Buy to Hold.

Notably, Synta announced last night ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE